

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/019,219 12/28/2001		Christophe Ronsin	065691-0263	1844
22428	7590 09/22/2004		EXAMINER	
FOLEY AND LARDNER			NICKOL, GARY B	
SUITE 500 3000 K STREET NW WASHINGTON, DC 20007			ART UNIT	PAPER NUMBER
			1642	
			DATE MAILED: 09/22/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

Applicant(s) Application No. 10/019,219 RONSIN ET AL. **Advisory Action** Examiner Art Unit 1642 Gary B. Nickol Ph.D. --The MAILING DATE of this communication appears on the cover sheet with the correspondence address --THE REPLY FILED 09 August 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

final re conditi	ore, further action by the applicant is required to avoid abandonment of this applicative spection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which on for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely nation (RCE) in compliance with 37 CFR 1.114.	places the application in			
	PERIOD FOR REPLY [check either a) or b)]				
a) 🛭	The period for reply expires <u>4</u> months from the mailing date of the final rejection.				
b) [no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE 706 07(f).	date of the final rejection. E FINAL REJECTION. See MPEP			
fee have fee unde (2) as se	tensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR be been filed is the date for purposes of determining the period of extension and the corresponding amouster 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply of et forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing led, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).	nt of the fee. The appropriate extension riginally set in the final Office action; or			
1.	A Notice of Appeal was filed on Appellant's Brief must be filed within the per 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of	iod set forth in the appeal.			
2.🛛	The proposed amendment(s) will not be entered because:				
(a) $oxtimes$ they raise new issues that would require further consideration and/or search (se	ee NOTE below);			
(b) they raise the issue of new matter (see Note below);				
(c))	ially reducing or simplifying the			
(d) they present additional claims without canceling a corresponding number of fine	nally rejected claims.			
	NOTE: See Continuation Sheet.				
	Applicant's reply has overcome the following rejection(s):				
4.🛛	Newly proposed or amended $claim(s)$ $\underline{1}$ and $\underline{2}$ would be allowable if submitted in a secanceling the non-allowable $claim(s)$.	eparate, timely filed amendment			
5.🖂	The a) \square affidavit, b) \square exhibit, or c) \boxtimes request for reconsideration has been consideration in condition for allowance because: <u>for the reasons of record</u> .	lered but does NOT place the			
6.	The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.				
7. For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.					
	The status of the claim(s) is (or will be) as follows:				
	Claim(s) allowed:				
	Claim(s) objected to:				
	Claim(s) rejected: <u>1-5,7,8,17,21-23 and 37</u> .				
	Claim(s) withdrawn from consideration: <u>6,9-16,18-20,24-36,38 and 39</u> .	•			
8.	The drawing correction filed on is a) approved or b) disapproved by the	ne Examiner.			
9.	Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)	*			
10.	Other:				
		Gangerine			
	Gary B. Nickol, Ph.D. Primary Examiner	Gary B. Nickol Ph.D. Primary Examiner			

Art Unit: 1642

Continuation of 2. NOTE: The proposed amendments to Claim 4 would require further searching and further considerations under 35 USC 112, 1st and 2nd paragraphs. Pharmaceutical compositions per se would remain rejected under 112, 1st paragraph, enablement.